Reviewing American Renal Associates (NYSE:ARA) and Baudax Bio (NYSE:BXRX)

American Renal Associates (NYSE:ARA) and Baudax Bio (NASDAQ:BXRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, risk, earnings and dividends.

Valuation and Earnings

This table compares American Renal Associates and Baudax Bio’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
American Renal Associates $805.78 million 0.37 -$28.77 million N/A N/A
Baudax Bio N/A N/A N/A N/A N/A

Baudax Bio has lower revenue, but higher earnings than American Renal Associates.

Institutional & Insider Ownership

85.4% of American Renal Associates shares are held by institutional investors. 9.4% of American Renal Associates shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares American Renal Associates and Baudax Bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
American Renal Associates -1.75% 23.16% 2.04%
Baudax Bio N/A N/A N/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for American Renal Associates and Baudax Bio, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
American Renal Associates 0 6 0 0 2.00
Baudax Bio 0 0 2 0 3.00

American Renal Associates presently has a consensus target price of $10.33, suggesting a potential upside of 12.32%. Baudax Bio has a consensus target price of $12.00, suggesting a potential upside of 105.13%. Given Baudax Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Baudax Bio is more favorable than American Renal Associates.

Summary

American Renal Associates beats Baudax Bio on 5 of the 9 factors compared between the two stocks.

American Renal Associates Company Profile

American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of June 30, 2018, it owned and operated 233 dialysis clinics in partnership with 400 nephrologist partners treating approximately 16,000 patients in 26 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.

Baudax Bio Company Profile

There is no company description available for Baudax Bio Inc.

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.